Meda's general meeting decided on merger with Cross Pharma

Meda's general meeting decided on merger with Cross Pharma The general meeting of Meda AB on 30 June 1999 approved the board's proposal on a new issue of 2 515 963 A-shares to Volati BV with payment by transfer of all shares in Cross Pharma AB. The merger between Meda AB and Cross Pharma AB takes place as per 30 June 1999. At the general meeting it was also announced that Cross Pharma has prematurely exercised its contractual right to repurchase Scandinavian Health Care's 50- percent holding in Cross Pharma A/S, operating in Norway. This means that Cross Pharma A/S takes over the entire parallel import operation in Norway as per 1 July 1999. For further information, please contact Annette Johansson Public Relations Manager Phone +46 31-701 29 04 or +46 70-445 03 00 Meda develops profitable partnerships in the Nordic and Baltic areas in collaboration with international producers of pharmaceuticals, nutrition and medical device products. With our thorough knowledge and our expertise in marketing and sales, we offer benefits to the health and medical care sector at the same time as we promote our own and our partner's growth and development. ------------------------------------------------------------ Please visit for further information The following files are available for download:

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.